Science Explorer Back to mapMap
Discussion
Researcher · IPO Porto · Portugal

Manuel Abecasis

Manuel Abecasis publishes mostly in Hematology, Immunology and Oncology, on topics such as Hematopoietic Stem Cell Transplantation, Chronic Myeloid Leukemia Treatments and Acute Lymphoblastic Leukemia research.

OpenAlex
World rank
#2,117,186
of 7,710,434 ranked researchers
Rank in Portugal
#9,308
of 41,760
Works
67
Citations
2.1k
Citations per work
31.9
h-index
18
i10-index 25Top 29% in Hematology
Manuel Abecasis

What does Manuel Abecasis research?

Manuel Abecasis's work is mostly in Medicine (39%), Immunology and Microbiology (9%), Biochemistry, Genetics and Molecular Biology (6%).

Everything else: 31 works · 46.3% of their workHealth Sciences: 26 works · 39.4% of their workMedicine: 26 works · 39.4% of their workHematology: 13 works · 18.9% of their workGenetics: 5 works · 7.4% of their workOncology: 5 works · 7.4% of their workEpidemiology: 4 works · 5.7% of their workLife Sciences: 10 works · 14.3% of their workImmunology and Microbiology: 6 works · 8.6% of their workImmunology: 6 works · 8.6% of their workBiochemistry, Genetics and Molecular Biology: 4 works · 5.7% of their workMolecular Biology: 4 works · 5.7% of their workTHEIR WORKManuel Abecasis67works
Life Sciences14%Health Sciences39%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
  1. Everything else3146.3%
    1. Medicine2639.4%
    1. Immunology and Microbiology68.6%
    2. Biochemistry, Genetics and Molecular Biology45.7%
  1. 1Hematology19% of their works
  2. 2Immunology9% of their works
  3. 3Oncology7% of their works
  4. 4Genetics7% of their works
  5. 5Epidemiology6% of their works
  6. 6Molecular Biology6% of their works

Research topics

Which keywords describe Manuel Abecasis's research?

The keywords of their largest research topics: Hematopoietic Stem Cells, Prognostic Factors, Bone Marrow Niche, Graft-versus-Host Disease, Acute Lymphoblastic Leukemia, Antifungal Therapy, BCR-ABL and Childhood Cancer.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 19 words, with their numbers
  1. Hematopoietic Stem Cells222 topics
  2. Prognostic Factors203 topics
  3. Bone Marrow Niche171 topic
  4. Graft-versus-Host Disease171 topic
  5. Acute Lymphoblastic Leukemia81 topic
  6. Antifungal Therapy82 topics
  7. BCR-ABL81 topic
  8. Childhood Cancer81 topic
  9. Imatinib81 topic
  10. Chronic Lymphocytic Leukemia71 topic
  11. Genomic Aberrations71 topic
  12. AML51 topic
  13. Acute Myeloid Leukemia51 topic
  14. Candidiasis41 topic
  15. Cryptococcal Disease41 topic
  16. Histoplasmosis41 topic
  17. Invasive Fungal Infections41 topic
  18. Merkel Cell Carcinoma41 topic
  19. Polyomavirus41 topic

Where does Manuel Abecasis work?

Manuel Abecasis's main affiliation in the publication record is IPO Porto, Portugal.

How many publications and citations does Manuel Abecasis have?

OpenAlex counts 67 works and 2,138 citations for Manuel Abecasis, an h-index of 18, ranking #2,117,186 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Manuel Abecasis. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.